Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Benmelstobart +/- Anlotinib in Resectable PD-L1 High NSCLC
NCT06851169Phase 2Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Apr 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of benmelstobart and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Tangdu Hospital. Primary endpoint: Complete Pathological Response. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
benmelstobartanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06851169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851169.